Contact Us | Print Page | Sign In | Register
News & Press: Industry News for MS (INforMS)

CMSC INforMS: Daclizumab approved (ZinbrytaTM) for relapsing forms of multiple sclerosis

Monday, October 10, 2016  
Posted by: Elizabeth Porco
Share |

The DECIDE trial compared daclizumab 150mg subcutaneous injection every 4 weeks with interferon (INF) beta-1a (Avonex) 30mcg once weekly for up 144 weeks. A total of 1841 patients (919 patients on daclizumab and 922 on INF beta 1a) with at least 2 relapses during the previous 3 years or at least 1 new brain lesion within the last 2 years were included. The adjusted annualized relapse rate was lower in the daclizumab group (0.22, 0.19-0.24, P<.001) than the INF beta-1a group (0.39, 0.35-0.44). The estimated percentage of patients with disability progression at week 144 was decreased with daclizumab but was not statistically significant (16% vs. 20% P=0.16).


Daclizumab labeling contains a black box warning for an increased risk for hepatic injury including autoimmune hepatitis as well as other immune mediated disorders such as skin reactions, lymphadenopathy, and non-infectious colitis. In the SELECT trial, 4% experienced ALT/AST elevations more than 5 times the upper normal limit, 3% of patients experienced serious infections, and less than 1% experienced serious cutaneous events. In the DECIDE trial, more patients experienced depression related events with daclizumab than INF beta-1. Other common side effects included injection site reactions, rash, and pharyngitis. Due to the risk of hepatic injury, daclizumab should not be used in combination with other hepatotoxic agents.

The effects of daclizumab during pregnancy and lactation of humans has not been studied. In monkeys administered daclizumab at 50mg/kg weekly, which produced an AUC approximately 30-50 times greater than the expected AUC in humans, no negative effects on fetal development were observed. It is not known if daclizumab is present in human milk, the effects on the breastfed child, or the effects on milk production.


The recommended dose of daclizumab is a 150mg subcutaneous injection every 4 weeks. If a dose is missed it should be administered no more than 2 weeks late. Daclizumab is available in 150mg single dose pre-filled syringes. Prior to administration the patient should remove the syringe from the refrigerator to allow the drug to warm to room temperature. If refrigeration is unavailable, daclizumab may be stored protected from light for up to 30 days at room temperature (86â—¦F). The drug should not be placed back in the refrigerator after being allowed to warm to room temperature and should be discarded after 30 days without refrigeration.

Daclizumab is contraindicated in patients with pre-existing hepatic disease. Daclizumab should not be started in patients with liver function tests showing ALT or AST at least 2 times greater than upper limit of normal.

Adam S. Whalley, PharmD is a PGY-1 pharmacy resident at UConn John Dempsey Hospital at UConn Health, Farmington, CT Kevin W. Charmberlin, PharmD is an associate clinical professor and assistant department head, pharmacy practice, UConn School of Pharmacy, Storrs, CT.

By Kevin W. Chamberlin, PharmD and Adam S. Whalley, PharmD

Modern Medicine Network

CMSC Disclaimer 
The industry news information and articles are for informational purposes only, and are not intended to represent any trends, partnerships, commitments, or research of the Consortium of MS Centers or any of it's members in any way whatsoever, nor should any party be libel in any way to the reader or to any other person, firm or corporation reading this industry news section. Although the CMSC site includes links providing direct access to other Internet sites, CMSC takes no responsibility for the content or information contained on those other sites, and does not exert any editorial or other control over those other sites. CMSC is providing information and services on the Internet as a benefit and service in furtherance of CMSC's nonprofit and tax-exempt status. CMSC makes no representations about the suitability of this information and these services for any purpose.

The Consortium of Multiple Sclerosis Centers

3 University Plaza Drive, Suite 116 Hackensack, NJ 07601

Tel: 201.487.1050 | Fax: 862.772.7275